Acute Lymphoblastic Leukemia — Expanded Access Programs
Overview
Right2Hope maintains a directory of 57 expanded access programs, clinical trials, and compassionate use pathways listed for Acute Lymphoblastic Leukemia. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with acute lymphoblastic leukemia programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 21 programs are currently active or recruiting, with the remaining 36 in other lifecycle stages. Sponsors actively running programs in this area include M.D. Anderson Cancer Center, Fred Hutchinson Cancer Center, St. Jude Children's Research Hospital, National Cancer Institute (NCI), Memorial Sloan Kettering Cancer Center, and others.
By recruiting status
Snapshot of where every Acute Lymphoblastic Leukemia program currently sits in its lifecycle.
- Active / Recruiting21
- Inactive36
Top sponsors
Organisations running the most Acute Lymphoblastic Leukemia programs in the directory.
- M.D. Anderson Cancer Center9 programs
- Fred Hutchinson Cancer Center6 programs
- St. Jude Children's Research Hospital6 programs
- National Cancer Institute (NCI)5 programs
- Memorial Sloan Kettering Cancer Center4 programs
- City of Hope Medical Center3 programs
- Masonic Cancer Center, University of Minnesota3 programs
- Center for International Blood and Marrow Transplant Research2 programs
- Children's Oncology Group2 programs
- AbbVie1 program
Acute Lymphoblastic Leukemia programs (57)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Study on 211^At-BC8-B10 Before Donor Stem Cell Transplant for High-Risk Leukemia and Related Conditions — Fred Hutchinson Cancer Center
- Study on Blinatumomab for Patients with Pre B-cell ALL and B-cell NHL After Stem Cell Transplant — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Study on Obecabtagene Autoleucel for People with B-cell Acute Lymphoblastic Leukemia — Memorial Sloan Kettering Cancer Center
- Study on Revumenib and Mezigdomide for Treating Leukemia — Memorial Sloan Kettering Cancer Center
- Extension Study for Patients Continuing Venetoclax Treatment from Previous Trials — AbbVie
- Study on Blinatumomab and Chemotherapy or Dasatinib, Prednisone, and Blinatumomab for Treating Older Adults with Acute Lymphoblastic Leukemia — National Cancer Institute (NCI)
- Study on Blinatumomab and Tyrosine Kinase Inhibitor Therapy for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia — Memorial Sloan Kettering Cancer Center
- CAR T Cell Therapy for Children, Teens, and Young Adults with CD19-Positive Leukemia — St. Jude Children's Research Hospital
- CD22 CAR T-Cell Therapy to Prolong Remission After CD19 CAR T-Cell Treatment in Children, Teens, and Adults with Relapsed or Hard-to-Treat B-cell Acute Lymphoblastic Leukemia — National Cancer Institute (NCI)
- Study on Chemotherapy With or Without Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia — National Cancer Institute (NCI)
- Study on Combination Chemotherapy With or Without Donor Stem Cell Transplant for Treating Acute Lymphoblastic Leukemia — National Cancer Institute (NCI)
- Cord Blood Transplantation for Children and Young Adults with Blood Cancer — Memorial Sloan Kettering Cancer Center
- Study on Essential Information for Starting Treatment in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma — St. Jude Children's Research Hospital
- Study on Using KIR-Favorable Donors for Transplants in Children with Certain Blood Cancers — Michael Pulsipher
- Study on Low-Intensity Chemotherapy, Ponatinib, and Blinatumomab for Treating Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia — M.D. Anderson Cancer Center
- CAR-T Cell Therapy for Blood Cancers: Study MT2017-45 — Masonic Cancer Center, University of Minnesota
- Study on Gene-Modified Donor T-Cells After Stem Cell Transplant for Blood Disorders — Bellicum Pharmaceuticals
- Study on Treatment for Newly Diagnosed B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma — St. Jude Children's Research Hospital
- Study on Total Therapy for Infants with Acute Lymphoblastic Leukemia (ALL) I — St. Jude Children's Research Hospital
- Total Therapy XVII for Newly Diagnosed Children with Acute Lymphoblastic Leukemia and Lymphoma — St. Jude Children's Research Hospital
- Study on Vedolizumab, Cyclophosphamide, and Tacrolimus to Prevent Graft Versus Host Disease in Patients Undergoing Stem Cell Transplant — City of Hope Medical Center
- Study on Bleximenib for Patients with Acute Leukemia — Janssen Research & Development, LLC
- Phase II Study of Ponatinib with Mini-hyper CVD Chemotherapy and Venetoclax for Patients with Relapsed or Hard-to-Treat T-cell Acute Lymphoblastic Leukemia — M.D. Anderson Cancer Center
- Study on Revumenib for Treating Relapsed or Refractory Leukemias with Specific Gene Changes — Syndax Pharmaceuticals
- Study on Using Modified CAR-T Cells with a Safety Switch for Treating Relapsed or Hard-to-Treat Acute Lymphoblastic Leukemia (ALL) — UNC Lineberger Comprehensive Cancer Center
- Study on Depleting Alpha/Beta T Cells and CD19+ B Cells in Stem Cell Transplants for Patients with Blood Cancers — University of Florida
- Study on Blinatumomab, Methotrexate, Cytarabine, and Ponatinib for Treating Philadelphia Chromosome-Positive or Relapsed/Refractory Acute Lymphoblastic Leukemia — M.D. Anderson Cancer Center
- Study on CAR T Cells Targeting CD19 and CD22 in Children and Young Adults with Hard-to-Treat B Cell Cancers — National Cancer Institute (NCI)
- Study on Cord Blood Transplant with Chemotherapy and Radiation for Treating High-Risk Blood Diseases — Fred Hutchinson Cancer Center
- Study on Cytokine-Treated Veto Cells for Patients with Blood Cancers After Stem Cell Transplant — M.D. Anderson Cancer Center
- Donor Stem Cell Transplant with Treosulfan, Fludarabine, and Total-Body Irradiation for Treating Blood Cancers — Fred Hutchinson Cancer Center
- Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel — Kite, A Gilead Company
- Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS) — Fred Hutchinson Cancer Center
- Study on HLA-Mismatched Unrelated Donor Stem Cell Transplant with Post-Transplant Cyclophosphamide — Center for International Blood and Marrow Transplant Research
- Study on HLA-Mismatched Unrelated Donor Stem Cell Transplant with Reduced Cyclophosphamide for Graft Versus Host Disease Prevention — Center for International Blood and Marrow Transplant Research
- Study on Using Expanded Cord Blood Cells with Single Cord Blood Transplant for Treating Blood Cancers — Fred Hutchinson Cancer Center
- Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation — M.D. Anderson Cancer Center
- Inotuzumab Ozogamicin for Children with MRD Positive CD22+ Lymphoblastic Leukemia — St. Jude Children's Research Hospital
- Study on Inotuzumab Ozogamicin for Treating B-cell Acute Lymphocytic Leukemia with Minimal Residual Disease — M.D. Anderson Cancer Center
- Study on Using Intrathecal Chemotherapy to Prevent Nerve Side Effects in Blinatumomab Treatment for Acute Lymphoblastic Leukemia — Northside Hospital, Inc.
- Study on JZP458 for Treating ALL/LBL Patients Allergic to E. Coli-derived Asparaginase — Jazz Pharmaceuticals
- Comparing Stem Cell Transplant Options for Young People with Acute Leukemia or Myelodysplastic Syndrome — Children's Oncology Group
- Study on T Cell Receptor Alpha/Beta Depletion Stem Cell Transplant for Blood Cancers — Masonic Cancer Center, University of Minnesota
- Study on Myeloablative Stem Cell Transplant with Donor for Blood Disorders — Masonic Cancer Center, University of Minnesota
- Naive T Cell Depletion to Prevent Chronic Graft-versus-Host Disease in Children and Young Adults with Blood Cancers Undergoing Donor Stem Cell Transplant — Fred Hutchinson Cancer Center
- Personalized NK Cell Therapy After Chemotherapy and Cord Blood Transplant for Blood Cancers — M.D. Anderson Cancer Center
- Phase 2 Study on the Safety and Effectiveness of Blinatumomab Injections for Patients with B-cell Acute Lymphoblastic Leukemia — M.D. Anderson Cancer Center
- Phase I/II Study of Rapcabtagene Autoleucel in CLL, Advanced DLBCL, ALL, and High-Risk LBCL — Novartis Pharmaceuticals
- Phase II Study of Blinatumomab and Asciminib for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia — M.D. Anderson Cancer Center
- Study on Reduced-Intensity Conditioning to Lower Treatment-Related Deaths in Patients Undergoing Stem Cell Transplant — Thomas Jefferson University
- Risk-Adapted Chemotherapy for Young Patients with Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma — Children's Oncology Group
- Study on Ruxolitinib with Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease in Young Patients Undergoing Bone Marrow Transplant for Leukemia or Myelodysplastic Syndrome — City of Hope Medical Center
- SPARK-ALL: Calaspargase Pegol for Adults with Acute Lymphoblastic Leukemia (ALL) — Institut de Recherches Internationales Servier
- Study on Chemotherapy-Free Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Using Inotuzumab Ozogamicin (InO) — University of Chicago
- Study on KTE-X19 for Patients with Minimal Residual Disease in B-Cell Acute Lymphoblastic Leukemia — H. Lee Moffitt Cancer Center and Research Institute
- Study on Using Siltuximab to Treat Side Effects of CAR-T Cell Therapy — University of Alabama at Birmingham
- Study on Total Marrow and Lymphoid Irradiation Before Stem Cell Transplant for Patients with Myelodysplastic Syndrome or Acute Leukemia — City of Hope Medical Center
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Acute Lymphoblastic Leukemia to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.